Rivaroxaban 10 mg or 7.5 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0791 | 0.0725 | 0.0862 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.082 | 0.0753 | 0.0892 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00293 | -0.0127 | 0.00681 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.964 | 0.855 | 1.09 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.961 | 0.843 | 1.1 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with a serious adverse event on Rivaroxaban 10 mg or 7.5 mg than on Placebo | 342 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Rivaroxaban 10 mg or 7.5 mg | Participants with a creatinine clearance (CrCl) greater than or equal to (\>=) 50 milliliter per minute (mL/min) received 10 milligram (mg) rivaroxaban tablet once daily orally and participants with a creatinine clearance from \>=30 to less than (\<) 50 mL/min at screening received 7.5 mg rivaroxaban tablet once daily orally for 45 days. | 475 | 6,007 | EG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Participants received rivaroxaban matched placebo tablet once daily orally for 45 days. | 493 | 6,012 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | Up to 75 days (+/-5 days) | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients | ClinicalTrials.gov |
| NCT number | NCT02111564 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases, Rheumatic Diseases | ClinicalTrials.gov |
| Interventions | Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg, Placebo | ClinicalTrials.gov |
| Lead sponsor | Janssen Research & Development, LLC | ClinicalTrials.gov |
| Results first posted | 2019-11-25 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02111564?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.